Holen Sie sich die Stockscreener-App
67.17
2.31%
-1.59
Handel nachbörslich:
67.17
Schlusskurs vom Vortag:
$68.76
Offen:
$68.2
24-Stunden-Volumen:
1.44M
Relative Volume:
0.57
Marktkapitalisierung:
$14.94B
Einnahmen:
$4.03B
Nettoeinkommen (Verlust:
$556.70M
KGV:
28.34
EPS:
2.37
Netto-Cashflow:
$970.10M
1W Leistung:
-1.31%
1M Leistung:
+5.46%
6M Leistung:
+4.16%
1J Leistung:
-16.06%
1-Tages-Spanne:
$67.14
$68.43
1-Wochen-Bereich:
$67.05
$69.03
52-Wochen-Spanne:
$51.90
$84.39
Hologic Inc Stock (HOLX) Company Profile
Firmenname
Hologic Inc
Sektor
Telefon
(508) 263-2900
Adresse
250 CAMPUS DRIVE, MARLBOROUGH, MA
Vergleichen Sie HOLX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HOLX
Hologic Inc
|
67.17 | 14.96B | 4.03B | 556.70M | 970.10M | 2.37 |
|
ISRG
Intuitive Surgical Inc
|
469.88 | 172.53B | 9.15B | 2.63B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
196.63 | 55.89B | 21.39B | 1.61B | 2.55B | 5.56 |
|
ALC
Alcon Inc
|
79.18 | 43.59B | 9.93B | 1.12B | 1.43B | 2.26 |
|
RMD
Resmed Inc
|
288.34 | 41.89B | 5.15B | 1.40B | 1.65B | 9.51 |
|
WST
West Pharmaceutical Services Inc
|
242.63 | 17.48B | 2.96B | 487.70M | 344.00M | 6.68 |
Hologic Inc Stock (HOLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-05-27 | Bestätigt | Needham | Hold |
| 2025-03-03 | Herabstufung | Argus | Buy → Hold |
| 2025-02-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-02-03 | Herabstufung | Needham | Buy → Hold |
| 2024-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-12-10 | Eingeleitet | Jefferies | Hold |
| 2024-12-10 | Bestätigt | Needham | Buy |
| 2024-10-01 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-06-27 | Eingeleitet | Stephens | Overweight |
| 2024-04-03 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-07-14 | Hochstufung | Needham | Hold → Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2022-07-20 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-07-20 | Eingeleitet | UBS | Neutral |
| 2022-07-18 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2021-12-15 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-07-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-11-20 | Herabstufung | Needham | Buy → Hold |
| 2020-11-05 | Bestätigt | Needham | Buy |
| 2020-06-30 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-06-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-04-30 | Bestätigt | Needham | Buy |
| 2020-04-30 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-04-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-03-27 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2020-01-13 | Bestätigt | Needham | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-09-26 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-08-01 | Bestätigt | Needham | Buy |
| 2019-05-02 | Bestätigt | Needham | Buy |
| 2019-01-31 | Bestätigt | Needham | Buy |
| 2019-01-02 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-10-09 | Eingeleitet | UBS | Neutral |
| 2018-09-13 | Herabstufung | BofA/Merrill | Buy → Neutral |
Alle ansehen
Hologic Inc Aktie (HOLX) Neueste Nachrichten
Hologic Inc. stock outperforms competitors on strong trading day - MarketWatch
What's Behind Hologic's Positive Long-Term Outlook For Cytology Unit? - Barchart.com
Here's Why Hologic (HOLX) is a Strong Value Stock - Yahoo Finance
What's Behind Hologic's Positive Long-Term Outlook for Cytology Unit? - Nasdaq
Stock Analysis | Hologic OutlookMixed Signals Amid Strong Fundamentals and Divergent Analyst Views - AInvest
Hologic Inc. Approaches Support With Recovery in Sight2025 Key Highlights & Reliable Trade Execution Plans - classian.co.kr
Argus Upgrades Hologic to Buy From Hold, Price Target is $80 - MarketScreener
Will Hologic Inc. benefit from current market trendsPortfolio Risk Summary & AI Powered Market Entry Strategies - sundaytimes.kr
What to Expect From Hologic's Q3 2025 Earnings Report - MSN
Does Hologic Inc. have high return on assets2025 Short Interest & Weekly High Potential Stock Alerts - classian.co.kr
Saliva-based Screening Market CAGR 7.70% Trends with Thermo - openPR.com
Hologic Reports Strong Q3 2025 Earnings, Exceeds Guidance - MSN
Stephens Adjusts Price Target on Hologic to $78 From $70 - MarketScreener
Is Trending Stock Hologic, Inc. (HOLX) a Buy Now? - Yahoo Finance
Hologic Eyes Organic Growth Rebound in 2026 on Breast Health Strength - MSN
Hologic Management to Meet Virtually with BTIG on August 21 - AInvest
Hologic's Growth Prospects and Undervalued Stock Support Buy Rating - AInvest
Hologic Stock Performance: Underperforms Market Despite Quarterly GainsNews and Statistics - IndexBox
What Are Wall Street Analysts' Target Price for Hologic Stock? - Yahoo Finance
Hologic Stock Target Price: A Closer Look - AInvest
What Are Wall Street Analysts' Target Price For Hologic Stock? - Barchart.com
Body Fat Measurement Market to Witness Growth and Comprehensive - openPR.com
Hologic’s Q2 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
HOLX Q2 Deep Dive: Breast Health Turnaround and New Product Launches Drive Momentum - FinancialContent
STD Diagnostic Market Forecast and Company Analysis Report - GlobeNewswire
STD Diagnostic Market Forecast and Company Analysis Report 2025-2033 Featuring Siemens, Abbott, MedMira, QIAGEN, Danaher, F. Hoffmann-La Roche, Diasorin, BioMeriuex, Hologic, Bio-Rad Laboratories - Yahoo Finance
Hologic's Diagnostics Arm Set for Long-Term Upside: What's Behind It? - MSN
Hologic's Diagnostics Arm Set For Long-Term Upside: What's Behind It? - Barchart.com
There May Be Some Bright Spots In Hologic's (NASDAQ:HOLX) Earnings - Yahoo Finance
RadNet hires Hologic, Bausch + Lomb alum Jane Mazur - Medical Marketing and Media
Hologic’s Growth Story Looks Set For A Comeback - Finimize
RBC Capital Reiterates Buy Rating for Hologic with $87 Price Target - AInvest
RBC Capital Upgrades Hologic (HOLX) to Outperform with Raised Pr - GuruFocus
Forecasting the Future: Next-Generation Biopsy-Based Cancer - openPR.com
Should You Buy, Sell or Hold Hologic Stock Post Q3 Earnings? - The Globe and Mail
Should You Buy, Sell Or Hold Hologic Stock Post Q3 Earnings? - Barchart.com
Hpv And Pap Testing Market Generated Opportunities, Future - openPR.com
RBC Capital Upgrades Hologic to Outperform From Sector Perform, Adjusts PT to $87 From $72 - MarketScreener
RBC Capital upgrades Hologic stock to Outperform on expected growth By Investing.com - Investing.com Canada
RBC Capital upgrades Hologic stock to Outperform on expected growth - Investing.com
Molecular Diagnostics Market Expands with Infectious Disease - openPR.com
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know - MSN
Analysts Have Made A Financial Statement On Hologic, Inc.'s (NASDAQ:HOLX) Third-Quarter Report - simplywall.st
Why Hologic (HOLX) is a Top Value Stock for the Long-Term - Yahoo Finance
Finanzdaten der Hologic Inc-Aktie (HOLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Hologic Inc-Aktie (HOLX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mitchell Essex D | Chief Operating Officer |
Dec 04 '24 |
Option Exercise |
62.60 |
22,902 |
1,433,659 |
52,813 |
| Mitchell Essex D | Chief Operating Officer |
Dec 04 '24 |
Sale |
76.34 |
24,856 |
1,897,482 |
27,957 |
0.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):